Antiinflammatory Effects of the Phosphodiesterase-4 Inhibitor Cilomilast (Ariflo) in Chronic Obstructive Pulmonary Disease

American Journal of Respiratory and Critical Care Medicine

Volumn 168, Issue 8, 2003, Pages 976-982

  Gamble, Elizabeth ^b   Grootendorst, Diana C ^b   Brightling, Christopher E ^b   Troy, Susannah ^b   Qiu, Yusheng ^b   Zhu, Jie ^b   Parker, Debbie ^b   Matin, Dean ^b   Majumdar, Swati ^b   Vignola, Antonio M ^b   Kroegel, Claus ^b   Morell, Ferran ^b   Hansel, Trevor T ^b   Rennard, Stephen I ^b   Compton, Christopher ^b   Amit, Ohad ^b   Tat, Tri ^b   Edelson, Jeffrey ^b   Pavord, Ian D ^b   Rabe, Klaus F ^b   Barnes, Neil C ^b   Jeffery, Peter K ^a   more..

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Bronchial biopsy; Chronic bronchitis; Emphysema; Induced sputum; Inflammation

Indexed keywords

CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CILOMILAST; INTERLEUKIN 8; LEUKOCYTE ELASTASE; PHOSPHODIESTERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHUS BIOPSY; CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DYSPEPSIA; FEMALE; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; HEART INFARCTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATORY CELL; LEUKOCYTE DIFFERENTIAL COUNT; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM EXAMINATION; SUPERNATANT; T LYMPHOCYTE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOPSY; BRONCHODILATOR AGENTS; CARBOXYLIC ACIDS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INTERLEUKIN-8; LEUKOCYTE COUNT; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; NITRILES; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM; TREATMENT OUTCOME;

EID: 0142012148     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200212-1490OC     Document Type: Article

References (43)

1. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997; 349:1498-1504.
2. Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma (Giles F. Filley Lecture). Chest 2000;117:251s-260s.
3. 1. Am J Respir Crit Care Med 1997;155:852-857.
4. Zhu J, Majumdar S, Qiu Y, Ansari T, Oliva A, Kips JC, Pauwels RA, De Rose V, Jeffery PK. Interleukin-4 and interleukin-5 gene expression and inflammation in the mucus-secreting glands and subepithelial tissue of smokers with chronic bronchitis. Am J Respir Crit Care Med 2001;164:2220-2228.
5. Zhu J, Qiu YS, Majumdar S, Gamble E, Matin D, Turato G, Fabbri LM, Barnes N, Saetta M, Jeffery PK. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for IL4, IL5 and eosinophil chemoattractants. Am J Respir Crit Care Med 2001;164:109-116.
6. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO global initiative for chronic obstructive pulmonary disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276.
7. Saetta M. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:822-826.
8. Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, Cavallesco G, Tropeano G, Mapp CE, Maestrelli P, et al. CD8+ cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:711-717.
9. Thompson AB, Daughton D, Robbins RA, Ghafouri MA, Oehlerking M, Rennard SI. Intraluminal airway inflammation in chronic bronchitis: characterization and correlation with clinical parameters. Am Rev Respir Dis 1989;140:1527-1537.
10. Lacoste J-Y, Bousquet J, Chanez P, Vyve TV, Simony-Lafontaine J, Lequeu N, Vic P, Enander I, Godard P, Michel F-B. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993;92:537-548.
11. 1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996;51:267-271.
12. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumour necrosis factor alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-534.
13. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, Wouters EF. Local and systemic inflammation in patients with COPD: soluble tumour necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002;166:1218-1224.
14. Churg A, Dai J, Tai H, Xie C, Wright JL. Tumour necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. Am J Respir Crit Care Med 2002;166: 849-854.
15. 1: The Lung Health Study. JAMA 1994;272:1497-1505.
16. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double-blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303.
17. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-548.
18. Yildiz F, Kaur AC, Ilgazli A, Celikoglu M, Kacar Ozkara S, Paksoy P, Ozkarakas O. Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration (Herrlisheim) 2000;67:71-76.
19. Hattotuwa KL, Gizycki M, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165:1592-1596.
20. Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, Nieman RB, Compton CH. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999; 12:131-135.
21. Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, Torphy TJ. SB 207499 (Ariflo), a potent and selective phophodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 1998;284:420-426.
22. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayres JG, Creemers JPHM, Schultze-Werninghaus G, Brambilla C, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001;358:265-270.
23. Pavord ID, Pizzichini MMM, Pizzichini E, Hargreave FE. The use of induced sputum to investigate airway inflammation. Thorax 1997;52: 498-501.
24. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord ID. Sputum eosinophilia and short-term response to pre- dnisblone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480-1485.
25. Saetta M, Turato G, Maesrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-1309.
26. Prieto A, Reyes E, Bernstein ED, Martinez B, Monserrat J, Izquierdo JL, Callol L, de Lucas P, Alvarez-Sala JL, Villarrubia VG, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (Inmunoferon). Am J Respir Crit Care Med 2001;163:1578-1583.
27. Cannon MJ, Openshaw PJ, Askonas BA. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 1988;168:1163-1168.
28. Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC, Rogers RM, Hayashi S, Hogg JC. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001;164:469-473.
29. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974; 291:755-758.
30. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, Mapp CE, Fabbri LM, Donner CF, Saetta M. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998;158:1277-1285.
31. Shapiro SD. The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:S29-S32.
32. Zhao MQ, Stoler MH, Liu AN, Wei B, Soguero C, Hahn YS, Enelow RI. Alveolar epithelial cell chemokine expression triggered by antigen-specific cytolytic CD8+ T cell recognition [abstract]. J Clin Invest 2000;106:R49-R58.
33. Peleman RA, Rytila PH, Kips JC, Joos GF, Pauwels RA. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur Respir J 1999;13:839-843.
34. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997;155:449-453.
35. Confalonieri M, Mainardi E, Della Porta R, Bernorio S, Gandola L, Beghe B, Spanevello A. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998;53:583-585.
36. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635-1639.
37. Culpitt SV, de Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:1371-1376.
38. Wright CD, Kuipers PJ, Kobylarz D, Singer L, Devall J, Klinkefus BA, Weishaar RE. Differential inhibition of human neutrophil functions: role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. Biochem Pharmacol 1990;40:699-707.
39. Maestrelli P, Saetta M, Di Stefano A, Calcagni PG, Turato G, Ruggieri MP, Roggeri A, Mapp CE, Fabbri LM. Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage. Am J Respir Crit Care Med 1995;152:1926-1931.
40. Pouw EM, Schols AMWJ, Deutz NEP, Wouters EFM. Plasma and muscle amino acid levels in relation to resting energy expenditure and inflammation in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:797-801.
41. Schols AMWJ, Buurman WA, Staal-van den Brekel AJ, Dentener MA, Wouters EFM. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51:819-824.
42. de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996;153:633-637.
43. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1398-1420.